SynthesisGastroenterology2016
Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.
Synthesis in Gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 5 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Quality indicators for upper GI endoscopy.Gastrointestinal endoscopy · 2025Guideline
- Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Pooled it
- Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis.Gastrointestinal endoscopy · 2022Pooled it
- Systematic review with meta-analysis: neoplasia detection rate and post-endoscopy Barrett's neoplasia in Barrett's oesophagus.Alimentary pharmacology & therapeutics · 2021Pooled it
- Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017Pooled it
- Texture and Colour Enhancement Imaging versus White Light Endoscopy for Detection of Dysplasia within Barrett's Oesophagus: A Pilot Study.Digestion · 2026Trial
- Artificial intelligence-enhanced volumetric laser endomicroscopy improves dysplasia detection in Barrett's esophagus in a randomized cross-over study.Scientific reports · 2022Trial
- Advances in the Diagnosis of Barrett's Esophagus.Diagnostics (Basel, Switzerland) · 2026Review
- The Tissue Systems Pathology Test Enabled Detection of Missed Prevalent High-Grade Dysplasia in a Presumed Clinically Low-Risk Patient With Nondysplastic Barrett's Esophagus.ACG case reports journal · 2026Article
- Epigenetic biomarkers and the progression of Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol.Systematic reviews · 2026Article
- Screening for Barrett's esophagus and esophageal adenocarcinoma: recent advances and next steps.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026Review
- Diagnostic and Prognostic Biomarkers for Barrett's Esophagus.Gastroenterology clinics of North America · 2026Review
- Standardizing clinical trials in near-infrared fluorescence imaging: a workflow and regulatory framework proposal.Npj imaging · 2026Review
- Discovery and Validation of Molecular Biomarkers for Differentiation of Nondysplastic Barrett's Esophagus from High-grade Dysplasia and Esophageal Adenocarcinoma.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Characteristics and causes of post-endoscopy Barrett's neoplasia: Retrospective multicenter study.Endoscopy international open · 2026Article
- Emerging Biomarkers for Managing Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026Review
- Barrett's esophagus: How can we miss high-grade dysplasia/cancer?Endoscopy international open · 2026Article
- Future of image enhanced endoscopy of esophageal adenocarcinoma.Clinical endoscopy · 2025Review
- Transforming Gastrointestinal Diagnosis with Molecular Endoscopy: Challenges and Opportunities.International journal of molecular sciences · 2025Review
- Quality Indicators for Upper GI Endoscopy.The American journal of gastroenterology · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsA proportion of patients with Barrett's esophagus (BE) are diagnosed with esophageal adenocarcinoma (EAC) within 1 year of an endoscopic examination that produced negative findings. These cases of missed cancers have not been well studied, despite current surveillance strategies for BE. We performed a systematic review and meta-analysis to determine the magnitude of missed EAC in cohorts of patients with BE.
methodsWe searched MEDLINE, EMBASE, and Web of Science from their inception to May 31, 2015 to identify cohort studies of adults with BE (baseline nondysplastic BE ± BE with low-grade dysplasia) and at least a 3-year follow-up period, providing data on missed and incident EACs (diagnosed within 1 year and diagnosed more than 1 year after the initial endoscopy in which BE was diagnosed, respectively). The main outcome measure was pooled proportion of missed and incident EACs (of all EACs detected after initial endoscopy) among BE cohorts, using a random effects model.
resultsIn a meta-analysis of 24 studies reporting on 820 missed and incident EACs, 25.3% were classified as missed (95% confidence interval: 16.4%-36.8%) and 74.7% as incident EACs (95% CI: 63.2%-83.6%), although there was substantial heterogeneity among studies (I2 = 74%). When the analysis was restricted to nondysplastic BE cohorts (15 studies), 23.9% of EACs were classified as missed (95% confidence interval: 15.3%-35.4%; I2 = 0%). In a meta-analysis of 10 studies with follow-up periods of ≥5 years (a total of 239 EACs), 22.0% were classified as missed (95% confidence interval: 8.7%-45.5%), with substantial heterogeneity (I2 = 68%).
conclusionsAmong adults with nondysplastic BE (or BE with low-grade dysplasia) at their index endoscopy and at least a 3-year follow-up period, 25% of EACs are diagnosed within 1 year after the index endoscopy. Additional resources should be allocated to detect missed EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.